Literature DB >> 16197704

A novel model for the investigation of orthotopically growing primary and secondary bone tumours using intravital microscopy.

F M Klenke1, T Merkle, J Fellenberg, A Abdollahi, P E Huber, M M Gebhard, V Ewerbeck, A Sckell.   

Abstract

Here is reported the development of an experimental model using intravital microscopy as a tool to orthotopically investigate malignant bone tumours. Although up to 85% of the most frequently occurring malignant solid tumours, such as lung and prostate carcinomas, metastasize into the bone, and despite the knowledge that a tumour's course may be altered by its surrounding tissue, there is no adequate experimental model available enabling the investigation of orthotopically grown bone tumours in vivo. Intravital microscopy is an internationally accepted experimental method, used in various acute and chronic animal models, that enables qualitative and quantitative analysis of the angiogenesis, microcirculation, growth behaviour, etc. of various benign and malignant tissues. Non-invasive investigations of up to several weeks are possible. Additionally, tissue samples can be taken after termination of the in vivo experiments for further ex vivo investigation (histology, immunohistochemistry, molecular biology, etc.), elucidating the mechanisms that underlie the in vivo observations. Severe combined immunodeficient mice were fitted with a cranial window preparation where the calvaria served as the site for orthotopic implantation of the solid human tumours Saos-2 osteosarcoma (primary) and A 549 lung carcinoma and PC-3 prostate carcinoma (secondary). In all preparations, the take rate was 100%. Histological assessment confirmed the data obtained in vivo, showing typical tumour growth with infiltration of the surrounding osseous and soft tissues. This novel model serves as a valuable tool in understanding the biology of primary and secondary bone tumours in physiological and pathophysiological situations, with implications for the most areas of tumour therapy such as chemotherapy, radiation and antiangiogenesis.

Entities:  

Mesh:

Year:  2005        PMID: 16197704     DOI: 10.1258/002367705774286411

Source DB:  PubMed          Journal:  Lab Anim        ISSN: 0023-6772            Impact factor:   2.471


  3 in total

1.  Celecoxib enhances radiation response of secondary bone tumors of a human non-small cell lung cancer via antiangiogenesis in vivo.

Authors:  Frank Michael Klenke; Amir Abdollahi; Marc Bischof; Martha-Maria Gebhard; Volker Ewerbeck; Peter E Huber; Axel Sckell
Journal:  Strahlenther Onkol       Date:  2010-12-23       Impact factor: 3.621

2.  The selective Cox-2 inhibitor Celecoxib suppresses angiogenesis and growth of secondary bone tumors: an intravital microscopy study in mice.

Authors:  Frank Michael Klenke; Martha-Maria Gebhard; Volker Ewerbeck; Amir Abdollahi; Peter E Huber; Axel Sckell
Journal:  BMC Cancer       Date:  2006-01-12       Impact factor: 4.430

3.  Tyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo.

Authors:  Frank M Klenke; Amir Abdollahi; Elisabeth Bertl; Martha-Maria Gebhard; Volker Ewerbeck; Peter E Huber; Axel Sckell
Journal:  BMC Cancer       Date:  2007-03-17       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.